Global Human Papillomavirus (HPV) Therapeutics Market 2019-2023
SKU ID : TNV-14770477 | Publishing Date : 28-Jan-2019 | No. of pages : 113
Detailed TOC of Global Human Papillomavirus (HPV) Therapeutics Market 2019-2023
PART 01: EXECUTIVE SUMMARYPART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: MARKET SEGMENTATION BY ROA
• Market segmentation by RoA
• Comparison by RoA
• Parenteral - Market size and forecast 2018-2023
• Topical - Market size and forecast 2018-2023
• Market opportunity by RoA
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• North America - Market size and forecast 2018-2023
• Europe - Market size and forecast 2018-2023
• Asia - Market size and forecast 2018-2023
• ROW - Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 09: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 10: MARKET TRENDS
PART 11: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive scenario
PART 12: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• ALLERGAN
• Bausch Health
• GlaxoSmithKline plc.
• Lee's Pharmaceutical Holdings Limited
• Merck Sharp & Dohme Corp.
PART 13: APPENDIX
• Research methodology
• List of abbreviations
Exhibit 01: Years in consideration
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: RoA - Market share 2018-2023 (%)
Exhibit 19: Comparison by RoA
Exhibit 20: Parenteral - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Parenteral - Year-over-year growth 2019-2023 (%)
Exhibit 22: Topical - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Topical - Year-over-year growth 2019-2023 (%)
Exhibit 24: Market opportunity by RoA
Exhibit 25: Customer landscape
Exhibit 26: Market share by geography 2018-2023 (%)
Exhibit 27: Geographic comparison
Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 29: North America - Year-over-year growth 2019-2023 (%)
Exhibit 30: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 31: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 32: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 33: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 34: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 36: Key leading countries
Exhibit 37: Market opportunity
Exhibit 38: Decision framework
Exhibit 39: Impact of drivers and challenges
Exhibit 40: Vendor landscape
Exhibit 41: Landscape disruption
Exhibit 42: Vendors covered
Exhibit 43: Vendor classification
Exhibit 44: Market positioning of vendors
Exhibit 45: ALLERGAN - Vendor overview
Exhibit 46: ALLERGAN - Product segments
Exhibit 47: ALLERGAN - Organizational developments
Exhibit 48: ALLERGAN - Geographic focus
Exhibit 49: ALLERGAN - Segment focus
Exhibit 50: ALLERGAN - Key offerings
Exhibit 51: ALLERGAN - Key customers
Exhibit 52: Bausch Health - Vendor overview
Exhibit 53: Bausch Health - Product segments
Exhibit 54: Bausch Health - Organizational developments
Exhibit 55: Bausch Health - Geographic focus
Exhibit 56: Bausch Health - Segment focus
Exhibit 57: Bausch Health - Key offerings
Exhibit 58: Bausch Health - Key customers
Exhibit 59: GlaxoSmithKline plc. - Vendor overview
Exhibit 60: GlaxoSmithKline plc. - Business segments
Exhibit 61: GlaxoSmithKline plc. - Organizational developments
Exhibit 62: GlaxoSmithKline plc. - Geographic focus
Exhibit 63: GlaxoSmithKline plc. - Segment focus
Exhibit 64: GlaxoSmithKline plc. - Key offerings
Exhibit 65: GlaxoSmithKline plc. - Key customers
Exhibit 66: Lee's Pharmaceutical Holdings Limited - Vendor overview
Exhibit 67: Lee's Pharmaceutical Holdings Limited - Business segments
Exhibit 68: Lee's Pharmaceutical Holdings Limited - Organizational developments
Exhibit 69: Lee's Pharmaceutical Holdings Limited - Segment focus
Exhibit 70: Lee's Pharmaceutical Holdings Limited - Key offerings
Exhibit 71: Lee's Pharmaceutical Holdings Limited - Key customers
Exhibit 72: Merck Sharp & Dohme Corp. - Vendor overview
Exhibit 73: Merck Sharp & Dohme Corp. - Business segments
Exhibit 74: Merck Sharp & Dohme Corp. - Organizational developments
Exhibit 75: Merck Sharp & Dohme Corp. - Geographic focus
Exhibit 76: Merck Sharp & Dohme Corp. - Segment focus
Exhibit 77: Merck Sharp & Dohme Corp. - Key offerings
Exhibit 78: Merck Sharp & Dohme Corp. - Key customers
Exhibit 79: Validation techniques employed for market sizing
Exhibit 80: List of abbreviations
Keyplayers in Global Human Papillomavirus (HPV) Therapeutics Market 2019-2023
ALLERGANBausch Health
GlaxoSmithKline
Lee's Pharmaceutical Holdings
Merck Sharp & Dohme